Low molecular weight heparin (dalteparin) as a "bridge-to-revascularisation" - one year follow-up of patients appropriate for early revascularisation in the noninvasive cohort of the FRISC2 trial

Lars Wallentin,Eva Swahn,F Kontny,Bo Lagerqvist,Steen Husted

Low molecular weight heparin (dalteparin) as a "bridge-to-revascularisation" - one year follow-up of patients appropriate for early revascularisation in the noninvasive cohort of the FRISC2 trial

2000

Lars Wallentin
Eva Swahn
F Kontny
Bo Lagerqvist
Steen Husted

Low molecular weight heparin (dalteparin) as a "bridge-to-revascularisation" - one year follow-up of patients appropriate for early revascularisation in the noninvasive cohort of the FRISC2 trial

Keywords:

Cohort
Cardiology
Low molecular weight heparin
Internal medicine
Medicine
Physical therapy
Surgery
Diabetes mellitus
one year follow up

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations